How to use this document
Copy the template below into your quality system. Replace every <<FILL: ...>> placeholder with your company, system, and process specifics, then route it through your own document control, review, and approval. The filled specimen shows one worked example; adapt the numbers and scope to your operation and verify each cited regulation or standard against the current source before you rely on it.
This is a generic, originally worded starting point. It contains no confidential, proprietary, or employer material, it is drafted with AI assistance and reviewed, it is not legal or compliance advice, and adopting it does not by itself create or prove compliance. See the Disclaimer and Terms.
This is a ready-to-use reference matrix for a validation, quality, or regulatory professional confirming which legal framework, and which modality-specific inspection risk, actually applies to a given program, rather than assuming it based on which modality feels most similar. Replace every <<FILL: ...>> placeholder with your own program’s specifics. A filled specimen follows.
1. Purpose
This matrix confirms, for each product or program in scope, the actual marketing pathway and governing regulation, the international counterpart, and the modality-specific inspection risk pattern to watch for, so that a validation or quality strategy is built against the framework that genuinely applies rather than one carried over by resemblance to a more familiar modality.
2. Framework reference
3. Program-specific classification
For each program in scope, confirm the classification explicitly rather than inheriting it from a similar-sounding prior program.
4. Modality-specific inspection risk
5. References
See the paired article, one validation mindset, six modalities, for the reasoning and worked history behind this matrix.
Confirm each regulation and pathway against its current, primary source before relying on this matrix for a live program; regulatory frameworks and effective dates change.
6. Revision history
7. Approvals
Filled specimen
Extract for Acme Therapeutics’ portfolio, spanning a legacy small molecule product and a newly in-licensed siRNA program.
Disposition note: ATX-410 was initially scoped internally by a validation team with prior monoclonal antibody experience as a likely BLA candidate, given the complexity of the lipid nanoparticle drug product. Section 3’s explicit classification review corrected this before the validation master plan was drafted, avoiding a control strategy built around the wrong specification philosophy and the wrong internal reviewer sign-off chain.
Common findings this matrix prevents
- A validation or specification strategy built around the wrong regulatory framework because a new modality was assumed to resemble the team’s more familiar prior experience.
- A device program still referencing 21 CFR 820 alone in current documentation without accounting for the Quality Management System Regulation’s incorporation of ISO 13485:2016.
- A nucleic acid drug program scoped internally as a biologic, with the wrong internal reviewer chain and specification philosophy, only discovered at the regulatory filing stage.
- No documented, dated confirmation of a program’s classification basis, leaving the decision as institutional memory rather than a traceable record.
How to adapt this matrix
- Add or remove modality rows to match your own portfolio; the six here are illustrative, not exhaustive.
- Complete Section 3 for every active program, even one that seems obviously classified, since the value of this matrix is catching the case that is not obvious.
- Revisit Section 2’s framework references at your standing regulatory intelligence review cadence; effective dates and pathway determinations do change.
